Literature DB >> 19641234

Effect of duration and intensity of ganciclovir exposure on lymphoblastoid cell toxicity.

Audrey Janoly-Dumenil1, Isabelle Rouvet, Nathalie Bleyzac, Yves Bertrand, Gilles Aulagner, Marie-Thérèse Zabot.   

Abstract

INTRODUCTION: Human cytomegalovirus infection is still a major complication after pediatric bone marrow transplantation and could be fatal in some cases. The toxicity of the drug in dividing transplanted haematopoietic cells combined with the suppression of cell growth caused by the virus remains a major problem in managing human cytomegalovirus infection.
METHODS: The aim of the current in vitro study was to evaluate the effect of the intensity (1-20 mg/l) and duration (1, 2, 7 or 14 days) of ganciclovir exposure on toxicity in B lymphoblastoid cells (using cell counting and viability measurements).
RESULTS: A correlation was found between the dose of ganciclovir exposure and a decrease in total cell number when duration exceeded 2 days (r(2)=0.92 and 0.93 after 7 and 14 days, respectively). High levels (20 mg/l) of ganciclovir were not more toxic than lowest levels (1 mg/l) for the shortest durations of ganciclovir exposure (1 and 2 days). Moreover, 50% cytotoxic concentrations markedly decreased with the duration of ganciclovir exposure (374-3 mg/l from 1 to 14 days respectively) after 14 days of culture.
CONCLUSIONS: This in vitro study demonstrated for the first time that ganciclovir exhibited an in vitro duration-dependent toxicity on haematopoietic-derived cells when in vivo doses of the drug were used.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19641234     DOI: 10.1177/095632020901900605

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  3 in total

Review 1.  Technical approaches to induce selective cell death of pluripotent stem cells.

Authors:  Ho-Chang Jeong; Seung-Ju Cho; Mi-Ok Lee; Hyuk-Jin Cha
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

2.  Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients.

Authors:  Thomas Horvatits; Reinhard Kitzberger; Andreas Drolz; Christian Zauner; Walter Jäger; Michaela Böhmdorfer; Stefanie Kraff; Achim Fritsch; Florian Thalhammer; Valentin Fuhrmann; Peter Schenk
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

3.  Repair of Ischemic Injury by Pluripotent Stem Cell Based Cell Therapy without Teratoma through Selective Photosensitivity.

Authors:  Seung-Ju Cho; So-Yeon Kim; Ho-Chang Jeong; Hyeonsik Cheong; Doseok Kim; Soon-Jung Park; Jong-Jin Choi; Hyongbum Kim; Hyung-Min Chung; Sung-Hwan Moon; Hyuk-Jin Cha
Journal:  Stem Cell Reports       Date:  2015-11-12       Impact factor: 7.765

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.